As Mer­ck buy­out buzz heats up, Seagen touts a pos­i­tive up­date on their Pad­cev/Keytru­da com­bo

Most of the news at Seagen these days re­volves around hot buzz about a po­ten­tial $40 bil­lion-plus Mer­ck buy­out. But to­day the fo­cus has shift­ed to an ex­per­i­men­tal com­bo that us­es the phar­ma gi­ant’s big PD-1 can­cer drug Keytru­da.

Ex­ecs at Seagen and their part­ner Astel­las post­ed pos­i­tive top-line num­bers for a com­bi­na­tion of Pad­cev and Keytru­da, not­ing a con­firmed over­all re­sponse rate of 64.5% for front­line urothe­lial can­cer pa­tients who are in­el­i­gi­ble for cis­platin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER